-
Mashup Score: 8Moderna plans to follow in Pfizer's footsteps, charge up to $130 for Covid-19 vaccine in U.S. - 1 year(s) ago
“This is the wrong move for public health and the wrong move for fighting the pandemic,” one critic said.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Moderna Provides Update on mRNA Vaccine Pipeline - 1 year(s) ago
The company is moving forward with vaccines to address respiratory and latent viruses as well as oncology.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 2Merck, Moderna detail potential skin cancer vaccine progress - 1 year(s) ago
Shares of Merck and Moderna jumped Tuesday after the drugmakers said a potential skin cancer vaccine they are developing using the same technology behind COVID-19 preventive shots fared well in a small study.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 9'New paradigm' moment as mRNA cancer vaccine developed - 1 year(s) ago
Pharma giants Merck and Moderna which developed the shot today heralded the results as ‘spectacular’ and a ‘tremendous step forward’. It targets high-risk melanoma.
Source: Mail OnlineCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 13
Moderna said its new booster appears to be more effective against Omicron variants than its original vaccine, and that it also seems effective against a new worrisome variant, BQ1.1.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2Moderna Omicron-Targeting Booster Candidates Demonstrate Superiority Over its Spikevax Booster - 1 year(s) ago
Safety profile in this study showed the frequency of adverse reactions with these boosters were similar or lower than that of either a second or third dose of the original vaccine.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 5Moderna says bivalent COVID-19 booster shot performs better against BA.5 omicron subvariant - 1 year(s) ago
Moderna released data from a Phase 2-3 clinical trial showing its bivalent COVID-19 booster shot performed better against the BA.4 and BA.5 omicron subvariants.
Source: ABC NewsCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Full Event Guide | mRNA-Based Therapeutics Summit Europe - 2 year(s) ago
Download your copy of the full event guide to find out more about our expert speaker faculty, agenda topics, and networking opportunities.
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0
The FDA has authorized bivalent COVID-19 vaccines from Moderna and Pfizer-BioNTech as a single booster dose in younger age groups.
Categories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0BIO's messy transition, mRNA's future, & Biogen's next CEO - 2 year(s) ago
What’s going on at biotech’s lobbying organization? Where does mRNA go from here? And what happens when startups close down? Find out on the latest episode of “The Readout LOUD” podcast. Listen now:
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
#Moderna plans to price its #Covid vaccine at anywhere from $110 to $130 per dose when the company pivots from a focus on government contracts to commercial distribution efforts. https://t.co/yIVYIZOzIb